North America Human Insulin Drugs Market Size (2024 - 2029)

The North America insulin market is projected to experience growth due to the increasing prevalence of diabetes, driven by factors such as sedentary lifestyles and obesity. The demand for insulin medications is rising as they play a crucial role in managing both type 1 and type 2 diabetes. Advances in insulin formulations and delivery methods are enhancing treatment effectiveness and convenience, making them more appealing to patients. Additionally, growing awareness of the benefits of early intervention and intensive glycemic control is leading to more aggressive treatment approaches, including earlier initiation of insulin therapy. Efforts to improve access and affordability, such as patient assistance programs, are also contributing to market expansion, despite ongoing challenges related to insulin costs and healthcare disparities.

Market Size of North America Human Insulin Drugs Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
North America Human Insulin Drugs Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
Market Size (2024) USD 11.58 Billion
Market Size (2029) USD 14.03 Billion
CAGR (2024 - 2029) 3.91 %
Market Concentration High

Major Players

North America Human Insulin Drugs Market Major Players

*Disclaimer: Major Players sorted in no particular order

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

North America Insulin Market Analysis

The North America Human Insulin Drugs Market size is estimated at USD 11.58 billion in 2024, and is expected to reach USD 14.03 billion by 2029, growing at a CAGR of 3.91% during the forecast period (2024-2029).

In North America, the prevalence of diabetes has been steadily increasing, in line with global trends. Sedentary lifestyles, poor dietary choices, and obesity are contributing factors to the rise in both type 1 and type 2 diabetes cases in the region. Consequently, there is a growing need for effective management strategies to tackle this public health issue.

A key element in managing diabetes in North America is the rising utilization of insulin medications. Insulin therapy remains crucial for individuals with type 1 diabetes and many patients with type 2 diabetes who require insulin to maintain optimal blood sugar levels. As the diabetes population continues to grow, the demand for insulin medications is expected to rise in the coming years.

Several factors are propelling the increased use of insulin medications in North America. Advances in insulin formulations and delivery methods have enhanced the effectiveness, safety, and convenience of insulin treatment, making it more attractive to patients. Newer insulin analogs provide quicker onset and longer-lasting effects, allowing for more flexible dosing schedules that closely resemble the body's natural insulin production.

Additionally, the growing awareness of the importance of early intervention and intensive glycemic control in preventing diabetes-related complications has led to more aggressive treatment approaches, including the initiation of insulin therapy at earlier stages of the disease. Healthcare providers are increasingly recognizing the benefits of early insulin initiation in preserving beta-cell function and improving long-term outcomes for patients with diabetes.

Furthermore, initiatives aimed at improving access to insulin, such as patient assistance programs and advocacy efforts to reduce insulin prices, are helping to ensure that individuals with diabetes can afford and access the medication they need. However, challenges such as insulin affordability and healthcare disparities continue to exist and require ongoing attention and action from policymakers, healthcare providers, and stakeholders across North America.

Overall, the increasing diabetes population in North America is driving greater usage of insulin drugs as a crucial component of diabetes management. With continued efforts to improve access, affordability, and innovation in insulin therapy, the region can work towards better outcomes for individuals living with diabetes.

Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.

North America Insulin Industry Segmentation

Human insulin, such as Myxredlin, Humulin R U-100, and Novolin R, can also be administered intravenously by healthcare professionals in a medical environment. During this process, doctors or nurses will diligently observe any potential side effects. It is important to note that while human insulin effectively manages elevated blood sugar levels, it does not provide a cure for diabetes. The North American human insulin drug market is segmented by drug and geography. The report offers the value (in USD) and volume (in units) for the above segments. 

Drug
Basal or Long-acting Insulin
Lantus (Insulin Glargine)
Levemir (Insulin Detemir)
Toujeo (Insulin Glargine)
Tresiba (Insulin Degludec)
Basaglar (Insulin Glargine)
Bolus or Fast-acting Insulin
NovoRapid/Novolog (Insulin Aspart)
Humalog (Insulin Lispro)
Apidra (Insulin Glulisine)
FIASP (Insulin aspart)
Admelog (Insulin lispro)
Traditional Human Insulin
Novolin/Actrapid/Insulatard
Humulin
Insuman
Combination Insulin
NovoMix (Biphasic Insulin Aspart)
Ryzodeg (Insulin Degludec and Insulin Aspart)
Xultophy (Insulin Degludec and Liraglutide)
Soliqua/Suliqua (Insulin glargine/Lixisenatide)
Biosimilar Insulin
Insulin Glargine Biosimilars
Human Insulin Biosimilars
Geography
United States
Canada
Rest of North America
Need A Different Region Or Segment?
Customize Now

North America Human Insulin Drugs Market Size Summary

The North American insulin market is experiencing a significant expansion, driven by the increasing prevalence of diabetes and the rising demand for effective management solutions. The region is witnessing a surge in insulin utilization, particularly due to advancements in insulin formulations and delivery methods that enhance treatment effectiveness and convenience. The growing awareness of the importance of early intervention and intensive glycemic control is also contributing to the increased adoption of insulin therapy. Despite challenges such as affordability and healthcare disparities, initiatives aimed at improving access to insulin are helping to ensure that individuals with diabetes can obtain the necessary medications. This dynamic landscape is expected to foster growth in the market over the forecast period.

The United States dominates the North American insulin market, accounting for a substantial share of the region's revenues. The high prevalence of diabetes, coupled with significant healthcare expenditure and the adoption of advanced therapeutics, positions the U.S. as a critical market for insulin drug manufacturers. Key players such as Novo Nordisk, Sanofi, and Eli Lilly hold significant market shares, with collaborations and innovations like oral insulin delivery systems and biosimilars further shaping the competitive landscape. The introduction of new therapies and products, along with regulatory approvals, is anticipated to drive market growth, making North America a pivotal region in the global insulin market.

Explore More

North America Human Insulin Drugs Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Drivers

    3. 1.3 Restraints

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Bargaining Power of Suppliers

      2. 1.4.2 Bargaining Power of Consumers

      3. 1.4.3 Threat of New Entrants

      4. 1.4.4 Threat of Substitute Products and Services

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION

    1. 2.1 Drug

      1. 2.1.1 Basal or Long-acting Insulin

        1. 2.1.1.1 Lantus (Insulin Glargine)

        2. 2.1.1.2 Levemir (Insulin Detemir)

        3. 2.1.1.3 Toujeo (Insulin Glargine)

        4. 2.1.1.4 Tresiba (Insulin Degludec)

        5. 2.1.1.5 Basaglar (Insulin Glargine)

      2. 2.1.2 Bolus or Fast-acting Insulin

        1. 2.1.2.1 NovoRapid/Novolog (Insulin Aspart)

        2. 2.1.2.2 Humalog (Insulin Lispro)

        3. 2.1.2.3 Apidra (Insulin Glulisine)

        4. 2.1.2.4 FIASP (Insulin aspart)

        5. 2.1.2.5 Admelog (Insulin lispro)

      3. 2.1.3 Traditional Human Insulin

        1. 2.1.3.1 Novolin/Actrapid/Insulatard

        2. 2.1.3.2 Humulin

        3. 2.1.3.3 Insuman

      4. 2.1.4 Combination Insulin

        1. 2.1.4.1 NovoMix (Biphasic Insulin Aspart)

        2. 2.1.4.2 Ryzodeg (Insulin Degludec and Insulin Aspart)

        3. 2.1.4.3 Xultophy (Insulin Degludec and Liraglutide)

        4. 2.1.4.4 Soliqua/Suliqua (Insulin glargine/Lixisenatide)

      5. 2.1.5 Biosimilar Insulin

        1. 2.1.5.1 Insulin Glargine Biosimilars

        2. 2.1.5.2 Human Insulin Biosimilars

    2. 2.2 Geography

      1. 2.2.1 United States

      2. 2.2.2 Canada

      3. 2.2.3 Rest of North America

North America Human Insulin Drugs Market Size FAQs

The North America Human Insulin Drugs Market size is expected to reach USD 11.58 billion in 2024 and grow at a CAGR of 3.91% to reach USD 14.03 billion by 2029.

In 2024, the North America Human Insulin Drugs Market size is expected to reach USD 11.58 billion.

North America Insulin Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)